These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28686256)

  • 1. Correction: Synthesis of l-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors.
    Putapatri SR; Kanwal A; Sridhar B; Banerjee SK; Kantevari S
    Org Biomol Chem; 2017 Jul; 15(28):6057. PubMed ID: 28686256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of L-rhamnose derived chiral bicyclic triazoles as novel sodium-glucose transporter (SGLT) inhibitors.
    Putapatri SR; Kanwal A; Sridhar B; Banerjee SK; Kantevari S
    Org Biomol Chem; 2014 Nov; 12(42):8415-21. PubMed ID: 25175761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of novel l-rhamnose derived acyclic C-nucleosides with substituted 1,2,3-triazole core as potent sodium-glucose co-transporter (SGLT) inhibitors.
    Putapatri SR; Kanwal A; Banerjee SK; Kantevari S
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1528-31. PubMed ID: 24556379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: Chiral NHC-catalyzed 1,3-dipolar [3 + 2] cycloaddition of azomethine imines with α-chloroaldehydes for the synthesis of bicyclic pyrazolidinones.
    Yang L; Lv Y; Wang F; Zhong G
    Org Biomol Chem; 2018 Aug; 16(32):5932. PubMed ID: 30083663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Potential of the Cerebral Sodium-Glucose Transporter as a Novel Therapeutic Target in Cerebral Ischemia].
    Yamazaki Y; Harada S; Tokuyama S
    Yakugaku Zasshi; 2018; 138(7):955-962. PubMed ID: 29962475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Iminosugars as glycosyltransferase inhibitors.
    Conforti I; Marra A
    Org Biomol Chem; 2021 Jun; 19(25):5660. PubMed ID: 34143164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction and removal of expression of concern: Enantio- and diastereocontrolled conversion of chiral epoxides to trans-cyclopropane carboxylates: application to the synthesis of cascarillic acid, grenadamide and l-(-)-CCG-II.
    Kumar P; Dubey A; Harbindu A
    Org Biomol Chem; 2020 Jul; 18(27):5264. PubMed ID: 32638808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter.
    Grempler R; Augustin R; Froehner S; Hildebrandt T; Simon E; Mark M; Eickelmann P
    FEBS Lett; 2012 Feb; 586(3):248-53. PubMed ID: 22212718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization.
    Chen HY; Chiu PY; Chang CJ; Tsai LL; Huang YL; Hsu JC
    Clin Drug Investig; 2018 Dec; 38(12):1125-1133. PubMed ID: 30219950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Synthesis and biological evaluation of pyrazolo-triazole hybrids as cytotoxic and apoptosis inducing agents.
    Srinivasa Reddy T; Kulhari H; Ganga Reddy V; Subba Rao AV; Bansal V; Kamal A; Shukla R
    Org Biomol Chem; 2019 Aug; 17(30):7247. PubMed ID: 31317166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose transporter as a novel therapeutic target in disease.
    Yamazaki Y; Harada S; Tokuyama S
    Eur J Pharmacol; 2018 Mar; 822():25-31. PubMed ID: 29329760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
    Dekkers CCJ; Gansevoort RT; Heerspink HJL
    Curr Diab Rep; 2018 Mar; 18(5):27. PubMed ID: 29589183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: Recent developments in the synthesis and applications of chiral ferrocene ligands and organocatalysts in asymmetric catalysis.
    Cunningham L; Benson A; Guiry PJ
    Org Biomol Chem; 2020 Dec; 18(46):9538. PubMed ID: 33231583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium influx through cerebral sodium-glucose transporter type 1 exacerbates the development of cerebral ischemic neuronal damage.
    Yamazaki Y; Harada S; Wada T; Hagiwara T; Yoshida S; Tokuyama S
    Eur J Pharmacol; 2017 Mar; 799():103-110. PubMed ID: 28174043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: Studies towards asymmetric synthesis of 4(S)-11-dihydroxydocosahexaenoic acid (diHDHA) featuring cross-coupling of chiral stannane under mild conditions.
    Wang R; He A; Ramu E; Falck JR
    Org Biomol Chem; 2015 Feb; 13(7):2196. PubMed ID: 25609001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose transporter type 3-mediated neuroprotective effect of acetylcholine suppresses the development of cerebral ischemic neuronal damage.
    Yamazaki Y; Harada S; Tokuyama S
    Neuroscience; 2014 Jun; 269():134-42. PubMed ID: 24699226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Synthesis and application of methyl itaconate-anthracene adducts in configuration assignment of chiral secondary alcohols by
    Rithchumpon P; Intakaew N; Khamto N; Yimklan S; Nimmanpipug P; Thavornyutikarn P; Meepowpan P
    Org Biomol Chem; 2021 Oct; 19(41):9081. PubMed ID: 34657953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of cerebral sodium-glucose transporter type 1 function mediated by post-ischemic hyperglycemia exacerbates the development of cerebral ischemia.
    Yamazaki Y; Ogihara S; Harada S; Tokuyama S
    Neuroscience; 2015 Dec; 310():674-85. PubMed ID: 26454021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.